tiprankstipranks
Trending News
More News >
Ocular Therapeutix Inc (OCUL)
:OCUL
US Market
Advertisement

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Compare
1,452 Followers
See the Price Targets and Ratings of:

OCUL Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Ocular
Therapeutix
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OCUL Stock 12 Month Forecast

Average Price Target

$20.50
▲(77.95% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is $20.50 with a high forecast of $31.00 and a low forecast of $14.00. The average price target represents a 77.95% change from the last price of $11.52.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","32":"$32","11.75":"$11.75","18.5":"$18.5","25.25":"$25.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,11.75,18.5,25.25,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,12.575384615384614,14.110769230769229,15.646153846153846,17.18153846153846,18.716923076923074,20.252307692307692,21.787692307692307,23.323076923076922,24.858461538461537,26.39384615384615,27.929230769230767,29.464615384615385,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,11.767692307692307,12.495384615384614,13.223076923076922,13.95076923076923,14.678461538461537,15.406153846153845,16.133846153846154,16.861538461538462,17.589230769230767,18.316923076923075,19.044615384615383,19.77230769230769,{"y":20.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,11.267692307692307,11.495384615384614,11.723076923076922,11.95076923076923,12.178461538461537,12.406153846153845,12.633846153846154,12.861538461538462,13.089230769230769,13.316923076923077,13.544615384615383,13.772307692307692,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$31.00Average Price Target$20.50Lowest Price Target$14.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on OCUL
H.C. Wainwright
H.C. Wainwright
$15$19
Buy
64.93%
Upside
Reiterated
10/08/25
Ocular Therapeutix price target raised to $19 from $15 at H.C. WainwrightOcular Therapeutix price target raised to $19 from $15 at H.C. Wainwright
Piper Sandler Analyst forecast on OCUL
Piper Sandler
Piper Sandler
$21$31
Buy
169.10%
Upside
Reiterated
10/03/25
Piper Sandler Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)
Robert W. Baird Analyst forecast on OCUL
Robert W. Baird
Robert W. Baird
$17$24
Buy
108.33%
Upside
Reiterated
10/03/25
Ocular Therapeutix price target raised to $24 from $17 at BairdOcular Therapeutix price target raised to $24 from $17 at Baird
Citizens JMP Analyst forecast on OCUL
Citizens JMP
Citizens JMP
$20$29
Buy
151.74%
Upside
Reiterated
10/01/25
Ocular Therapeutix price target raised to $29 from $20 at Citizens JMPOcular Therapeutix price target raised to $29 from $20 at Citizens JMP
William Blair
Buy
Reiterated
10/01/25
Ocular Therapeutix's Strategic Initiatives and Clinical Advancements Drive Buy Rating9:37 AM Research | Healthcare Ocular Therapeutix, Inc. (OCUL) $11.69 Market Value (M): $2,034 Biotechnology Lachlan Hanbury-Brown +1 312 364 8125 lhanbury- Phase III Plans in DR It, as Ocular hosted an investor day in New York, where it provided updates on its ongoing SOL-1 and SOL-R studies of Axpaxli in wet AMD (wAMD), outlined the design of the SOL-X open-label extension study, introduced its plans for pivotal studies of Axpaxli in nonproliferative diabetic retinopathy (NPDR), and reviewed the commercial opportunity for Axpaxli in retinal vascular disorders.
Needham
$15$20
Buy
73.61%
Upside
Reiterated
10/01/25
Ocular Therapeutix: Buy Rating Affirmed Amid Promising Clinical Advancements and Strong Financial Position
RBC Capital Analyst forecast on OCUL
RBC Capital
RBC Capital
$17
Buy
47.57%
Upside
Reiterated
10/01/25
RBC Capital Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)
Bank of America Securities Analyst forecast on OCUL
Bank of America Securities
Bank of America Securities
$18
Buy
56.25%
Upside
Reiterated
10/01/25
Buy Rating for Ocular Therapeutix Driven by Strategic Advancements and Promising Clinical Trials in Diabetic Retinopathy
Chardan Capital Analyst forecast on OCUL
Chardan Capital
Chardan Capital
$21
Buy
82.29%
Upside
Initiated
09/15/25
Ocular Therapeutix initiated with a Buy at ChardanOcular Therapeutix initiated with a Buy at Chardan
Scotiabank Analyst forecast on OCUL
Scotiabank
Scotiabank
$22$20
Buy
73.61%
Upside
Reiterated
08/06/25
Scotiabank Remains a Buy on Ocular Therapeutix (OCUL)
Clear Street Analyst forecast on OCUL
Clear Street
Clear Street
$18
Buy
56.25%
Upside
Reiterated
08/05/25
Clear Street reiterates Buy Rating on Ocular Therapeutix (OCUL)Clear Street analyst Bill Maughan reiterated a Buy rating and $18.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
TD Cowen
$14
Buy
21.53%
Upside
Reiterated
08/05/25
TD Cowen on Ocular Therapeutix (OCUL): SOL-1 Data In Q1:2026 Should Be Positive And Clinically RelevantTD Cowen analyst Tara Bancroft reiterated a Buy rating and $14.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
Raymond James Analyst forecast on OCUL
Raymond James
Raymond James
$19
Buy
64.93%
Upside
Reiterated
08/04/25
Raymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)Raymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on OCUL
H.C. Wainwright
H.C. Wainwright
$15$19
Buy
64.93%
Upside
Reiterated
10/08/25
Ocular Therapeutix price target raised to $19 from $15 at H.C. WainwrightOcular Therapeutix price target raised to $19 from $15 at H.C. Wainwright
Piper Sandler Analyst forecast on OCUL
Piper Sandler
Piper Sandler
$21$31
Buy
169.10%
Upside
Reiterated
10/03/25
Piper Sandler Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)
Robert W. Baird Analyst forecast on OCUL
Robert W. Baird
Robert W. Baird
$17$24
Buy
108.33%
Upside
Reiterated
10/03/25
Ocular Therapeutix price target raised to $24 from $17 at BairdOcular Therapeutix price target raised to $24 from $17 at Baird
Citizens JMP Analyst forecast on OCUL
Citizens JMP
Citizens JMP
$20$29
Buy
151.74%
Upside
Reiterated
10/01/25
Ocular Therapeutix price target raised to $29 from $20 at Citizens JMPOcular Therapeutix price target raised to $29 from $20 at Citizens JMP
William Blair
Buy
Reiterated
10/01/25
Ocular Therapeutix's Strategic Initiatives and Clinical Advancements Drive Buy Rating9:37 AM Research | Healthcare Ocular Therapeutix, Inc. (OCUL) $11.69 Market Value (M): $2,034 Biotechnology Lachlan Hanbury-Brown +1 312 364 8125 lhanbury- Phase III Plans in DR It, as Ocular hosted an investor day in New York, where it provided updates on its ongoing SOL-1 and SOL-R studies of Axpaxli in wet AMD (wAMD), outlined the design of the SOL-X open-label extension study, introduced its plans for pivotal studies of Axpaxli in nonproliferative diabetic retinopathy (NPDR), and reviewed the commercial opportunity for Axpaxli in retinal vascular disorders.
Needham
$15$20
Buy
73.61%
Upside
Reiterated
10/01/25
Ocular Therapeutix: Buy Rating Affirmed Amid Promising Clinical Advancements and Strong Financial Position
RBC Capital Analyst forecast on OCUL
RBC Capital
RBC Capital
$17
Buy
47.57%
Upside
Reiterated
10/01/25
RBC Capital Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)
Bank of America Securities Analyst forecast on OCUL
Bank of America Securities
Bank of America Securities
$18
Buy
56.25%
Upside
Reiterated
10/01/25
Buy Rating for Ocular Therapeutix Driven by Strategic Advancements and Promising Clinical Trials in Diabetic Retinopathy
Chardan Capital Analyst forecast on OCUL
Chardan Capital
Chardan Capital
$21
Buy
82.29%
Upside
Initiated
09/15/25
Ocular Therapeutix initiated with a Buy at ChardanOcular Therapeutix initiated with a Buy at Chardan
Scotiabank Analyst forecast on OCUL
Scotiabank
Scotiabank
$22$20
Buy
73.61%
Upside
Reiterated
08/06/25
Scotiabank Remains a Buy on Ocular Therapeutix (OCUL)
Clear Street Analyst forecast on OCUL
Clear Street
Clear Street
$18
Buy
56.25%
Upside
Reiterated
08/05/25
Clear Street reiterates Buy Rating on Ocular Therapeutix (OCUL)Clear Street analyst Bill Maughan reiterated a Buy rating and $18.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
TD Cowen
$14
Buy
21.53%
Upside
Reiterated
08/05/25
TD Cowen on Ocular Therapeutix (OCUL): SOL-1 Data In Q1:2026 Should Be Positive And Clinically RelevantTD Cowen analyst Tara Bancroft reiterated a Buy rating and $14.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
Raymond James Analyst forecast on OCUL
Raymond James
Raymond James
$19
Buy
64.93%
Upside
Reiterated
08/04/25
Raymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)Raymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ocular Therapeutix

1 Month
xxx
Success Rate
9/19 ratings generated profit
47%
Average Return
+7.38%
reiterated a xxx
rating 22 hours ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.37% of your transactions generating a profit, with an average return of +7.38% per trade.
3 Months
xxx
Success Rate
18/33 ratings generated profit
55%
Average Return
+9.31%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +9.31% per trade.
1 Year
Yi ChenH.C. Wainwright
Success Rate
13/19 ratings generated profit
68%
Average Return
+49.41%
reiterated a buy rating 22 hours ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +49.41% per trade.
2 Years
xxx
Success Rate
30/33 ratings generated profit
91%
Average Return
+92.32%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +92.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OCUL Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
17
13
4
4
10
Buy
3
2
7
7
8
Hold
7
8
5
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
23
16
14
20
In the current month, OCUL has received 18 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. OCUL average Analyst price target in the past 3 months is 20.50.
Each month's total comprises the sum of three months' worth of ratings.

OCUL Financial Forecast

OCUL Earnings Forecast

Next quarter’s earnings estimate for OCUL is -$0.37 with a range of -$0.41 to -$0.33. The previous quarter’s EPS was -$0.39. OCUL beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year OCUL has Preformed in-line its overall industry.
Next quarter’s earnings estimate for OCUL is -$0.37 with a range of -$0.41 to -$0.33. The previous quarter’s EPS was -$0.39. OCUL beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year OCUL has Preformed in-line its overall industry.

OCUL Sales Forecast

Next quarter’s sales forecast for OCUL is $14.63M with a range of $12.57M to $19.00M. The previous quarter’s sales results were $13.46M. OCUL beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year OCUL has Preformed in-line its overall industry.
Next quarter’s sales forecast for OCUL is $14.63M with a range of $12.57M to $19.00M. The previous quarter’s sales results were $13.46M. OCUL beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year OCUL has Preformed in-line its overall industry.

OCUL Stock Forecast FAQ

What is OCUL’s average 12-month price target, according to analysts?
Based on analyst ratings, Ocular Therapeutix Inc’s 12-month average price target is 20.50.
    What is OCUL’s upside potential, based on the analysts’ average price target?
    Ocular Therapeutix Inc has 77.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is OCUL a Buy, Sell or Hold?
          Ocular Therapeutix Inc has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ocular Therapeutix Inc’s price target?
            The average price target for Ocular Therapeutix Inc is 20.50. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $31.00 ,the lowest forecast is $14.00. The average price target represents 77.95% Increase from the current price of $11.52.
              What do analysts say about Ocular Therapeutix Inc?
              Ocular Therapeutix Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of OCUL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis